call-btn
Medicover email
Medicover Logo
☰
Home | Doctors | Dr Srividya N

Dr Srividya N

Dr Srividya N

MBBS, MD, DM(Medical oncologists)
Consultant Medical Oncologist
Experience: 8 Years
Location: Nellore


About Doctor:

  • Chemotherapy
  • Targeted therapy Immunotherapy
  • Colon & GI Cancer
  • Kidney & GU Cancer
  • Breast Cancer Treatment
  • Lung cancer
  • Leukemia
  • Lymphoma
  • Myeloma
  • Pediatric oncology
  • Cancer Screening
  • Ovary Cancer
  • Bone Cancer
  • Thyroid Cancer Palliative treatment Transplant
  • 2012-2015 - Senior Resident at Nims, Hyderabad
  • 2015-2016 - Senior Resident at Ggh, Guntur
  • 2015-2018 - Consultant Medical Oncologist at City Cancer Center, Vijayawada
  • 2018- March 2021 - Consultant Medical Oncologist at Hcg, Vijayawada
  • April 2021 -till Date - Consultant Medical Oncologist Medicover Cancer Institute, Nellore
  • Response to Imatinib Mesylate in Childhood Chronic Myeloid Leukemia in Chronic Phase”, South Asian J Cancer 2014 Oct;3(4):203-5.
  • Impact of Imatinib compliance on the cytogenetic response at six months in pediatric CML CP. Indian Journal of Pediatrics 2016 Feb 3. DOI 10.1007/s12098-015-2007-9.
  • Impact of treatment protocol on outcome of localized Ewing’s sarcoma. South Asian J Cancer 2016;5:194-5
  • Trends in management of acute lymphoblastic leukemia: Influence of Insurance based healthcare and treatment compliance on the outcome of adolescents and aduls with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 2016 Jan-Mar; 37 (1):32-7
  • Cytogenetic and Molecular response among EUTOS risk groups in children with CML CP on Imatinib treatment. Egypt J Haematol 2017;42:74-7.
  • Effectiveness of three prognostic scoring systems in predicting the response and outcome in pediatric CML CP on frontline Imatinib. Indian J Med Paediatr Oncol 2017;38:282-6.Imatinib dose hike in suboptimal response and failure in CML CP: Results from a developing nation. journal of Clinical oncology 31,2013_suppl e18003
  • Cytogenetic and molecular response rates in AYA CML CP patients on imatinib based on the baseline BMI”, Annals of Oncology, Volume 27, Issue suppl_9, December 2016, mdw586.009,
  • Safety and efficacy of Carboplatin, Capecitabine plus Cetuximab biweekly regimen in the first-line treatment of patients with recurrent/metastatic head and neck cancer (R/MSCCHN): Single center, retrospective study. Annals of Oncology, Volume 29, Issue suppl_9, November 2018, mdy438.029.
  • Prognostic significance of NLR kinetics in operable triple negative breast cancer. e14201 journal of Clinical oncology 37,2019, no.15_suppl.
  • English
  • తెలుగు
  • हिन्दी
  • American Society of Clinical Oncology
  • European Society of Medical Oncology
  • Indian Society of Immuno-oncology

Copyrights © 2022 All Rights Reserved by Medicover Hospitals (A Unit of Sahrudaya Health Care Private Limited)